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Abstract
We address here the issue of prioritizing non-coding mutations in the tumoral genome. To
this aim, we created two independent computational models. The first (germline) model
estimates purifying selection based on population SNP data. The second (somatic) model
estimates tumor mutation density based on whole genome tumor sequencing. We show
that each model reflects a different set of constraints acting either on the normal or tumor
genome, and we identify the specific genome features that most contribute to these con-
straints. Importantly, we show that the somatic mutation model carries independent func-
tional information that can be used to narrow down the non-coding regions that may be
relevant to cancer progression. On this basis, we identify positions in non-coding RNAs and
the non-coding parts of mRNAs that are both under purifying selection in the germline and
protected from mutation in tumors, thus introducing a new strategy for future detection of
cancer driver elements in the expressed non-coding genome.
Author Summary
Cancer cells undergo a mutation/selection process that resembles that of any living cell.
Most mutations in cancer cell DNA occur in the so-called "non-coding" regions that repre-
sent 98.5% of the genome length. Pinning down which of these mutations contribute to
the fitness of cancer cells would be important for identifying new "cancer drivers", which
may in turn lead to future treatments. Unfortunately, predicting the impact of a non-cod-
ing DNA alteration remains extremely difficult. In this study, we analyze millions of non-
coding cancer mutations and show cancer-specific mutational patterns can be used to
predict non-coding regions that are preserved from mutations and may thus be important
for cancer cell survival. Combining this information with population data, we propose a
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new scoring system that should help prioritize important non-coding mutations in future
studies.
Introduction
Since the onset of cancer genomics, the search for cancer genes and cancer-causing mutations
has largely focused on protein-coding genes and, more specifically, their coding exons, where
the damaging effect of mutations is best understood. Among 572 human genes considered as
cancer drivers [1,2], nearly all are protein-coding. However protein-coding regions only repre-
sent a tiny subset of the vast transcribed area composed of over 50,000 non-coding genes [3,4]
and the introns and untranslated regions (UTRs) of mRNA genes. Even though a large part of
the non-coding transcribed regions is probably non functional [5], analyses based on evolu-
tionary conservation or allele frequencies in human populations [6,7] estimate that 10 to 15%
of the overall genome is under selection, that is 7–10 times larger than protein-coding regions.
Non-coding mutations may cause damage in many distinct ways. They may alter RNA
structure [8] or binding sites for proteins or other RNAs, such as splicing sites [9] and micro-
RNA target sites in 3’ UTRs, or impact regulatory sequences in gene promoters and enhancers.
A recent population genomics study estimates that there are in average 15 highly deleterious
mutations in the non-coding DNA of any healthy individual [10]. This large source of poten-
tially damaging mutation remains mostly untouched by cancer genomics. In-depth analysis of
the mutational load in the non-coding fraction of the genome is needed for the comprehensive
understanding of cancer progression, as well as for the identification of new cancer drivers and
therapeutic targets.
Whole genome normal vs. tumor sequencing commonly reveals thousands to tens of thou-
sands of somatic mutations [11–13], scattered across all genomic areas. In coding regions the
genetic code and aminoacid conservation rules provide a robust functional model for scoring
mutational damage [14,15]. Similarly reliable tools are needed for non-coding regions in order
to prioritize non-coding mutations and seek gene regions acquiring deleterious mutations at
an unusual pace across a set of tumor samples. Several scoring systems for non-coding muta-
tions already exist. The RegulomeDB system [16] scores variants using an empirical metric
based on their overlap with transcription factor (TF) motifs, known TF binding site, chromatin
marks or expression QTLs (eQTL) and thus is clearly centered on regulatory DNA variants.
Other scoring models consider allele frequencies in human populations. Rare alleles are more
often associated to reduced or lost gene activity than frequent alleles [17] and a high local ratio
of rare to total SNP is indicative of purifying selection [10,18–20]. Khurana et al. used SNP
data from the 1000 Genome project [21] to identify about 0,4% of the genome (12Mb) as
sensitive to mutations and introduced an empirical scoring system (Funseq) to rate somatic
mutations based on their presence in sensitive segments and overlap with known regulatory
elements [10,22]. Likewise, the CADD system [23] predicts the deleteriousness of non-coding
mutations based on allele frequencies modeled using machine learning on a series of genome
features. Recently, Ritchie et al. introduced a model for prioritizing non-coding variants based
on databases of known disease-related mutations [24]. The authors used machine learning to
predict regions where disease-causing variants are most likely, using as explanatory variables
functional features such as exon annotations, histone and other chromatin marks or transcrip-
tion factor binding sites (TFBS). However useful, these models have limitations in that they
are often directed towards the detection of regulatory elements (where 75% of disease variants
have been located to date [24] and they only consider human mutations in the light of
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germline, evolutionary selection, meaning independently of a specific tissue or disease context.
This latter point is especially important in cancer, where (1) most disease-inducing mutations
occur somatically during the lifetime of an individual, and (2) these mutations may have differ-
ent impacts when occurring in different tissues.
The availability of multiple whole genome sequence (WGS) data from tumors and matched
normal tissue has revealed the extensiveness and singularity of cancer somatic mutations [11–
13]. Cancer cells divide under their own set of selective constraints by which large regions of
the genome can sustain high mutation rates while others seem relatively protected. This accel-
erated mutation rate is an important factor that may cause recurrent mutations in genome
areas that are not necessarily related to cancer. Methods for scoring putative driver mutations
now take such effect into account [13].
Variation of the somatic mutation rates in different genome areas is by itself a rich source of
functional information. Schuster-Böckler & Lehner [25] related 45 functional features (mostly
histone marks) to somatic mutation rates and observed that the major factor influencing muta-
tion density was chromatin organization, marks of open chromatin being associated to a
reduced SNV densities and marks of closed chromatin to higher densities. Cancer somatic
mutations do not all cause cell death or tumor progression, but they may contribute to tumor
heterogeneity which in turn facilitates the emergence of new clones capable of surviving micro-
environmental changes and drug treatments [26]. In this sense, the somatic mutation land-
scape can be considered as a model of accelerated evolution in which most mutations are neu-
tral and a handful is under selection as beneficial to tumor progression.
A strong hypothesis guiding the present study is that, in order to prioritize non-coding
mutations in cancer and eventually discover new cancer drivers, one should take into account
these dual selection forces acting on the tumor genome: (1) population and evolutionary con-
straints acting at germline level and (2) constraints resulting from the accelerated mutation
background of the cancer tissue. To this aim we developed two integrative models that use
annotated genome features to predict germline or somatic mutation constraints at any genomic
location. We compared the functional features that most influence each mutational regimen
and analyzed the intersection of constrained regions predicted under each model. A new pic-
ture of the somatic mutational landscape emerges where regions under constraint in the germ-
line may be subject to highly variable mutation rates in the tumor. We present evidence that
low somatic mutation areas are functionally relevant and can be used as a powerful screen for
prioritizing cancer-related non-coding mutations.
Results
We represent germline and somatic constraints acting on tumor genomes using two indepen-
dent models, one for each mutational regimen, that we term the SNP model and the SOM
model. For each model, we define a set of genome features, mainly from UCSC/Ensembl
genome annotation and the ENCODE Project [27] and we use these features to predict the
expected mutational constraint at any genome position. In the SNP model, the mutational con-
straint is expressed as a regional ratio of rare SNP, while in the SOMmodel it is expressed as a
regional mutation density. We further describe each model below.
Scoring mutations with the germline (SNP) model
A high regional ratio of rare SNPs (i.e. SNPs with allele frequencies below 0.5 or 1%) is a hall-
mark of genome regions under negative / purifying selection [10,18,20]. Fig 1A shows varying
ratios of rare SNPs obtained from the 1000 Genome Project [21] associated to known func-
tional regions or "features‴ (see S1 Table for each feature definition). Coding regions (CDS)
Scoring Non-coding Cancer Mutations
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Fig 1. Construction of the rare SNPmodel. A. Fraction of rare SNPs (allele frequency <0.01) according to different genome features (see S1 Table and
Methods for feature details). Each box shows rare SNP fraction across all human chromosomes, except chr. Y. CDS: coding sequence; cTFBS: conserved
transcription factor binding site; CR: evolutionarily conserved region; UTR: untranslated region; Sensitive: region with high rate of rare SNP defined in [10],
ER/LR: early and late replicated region; DNase: DNase I hypersensitive site; HE/LE: high and low expressed region; Intron L/Intron P: intron of lncRNA/of
protein coding gene; ncExon: non coding exon; ECS: evolutionarily conserved structure; RR H/RR L/GC H/GC L: high recombination rate, low recombination
rate, high GC content and low GC content regions. The red dotted line represents the average fraction of rare SNPs across the genome.B. Feature
importance as measured by IncNodePurity. We only show here features that passed feature selection.C. Distribution of SNP scores for random SNPs and
for clinical variants from the Clivariants and HGMD databases. Random SNPs here are a set of 1M random intergenic SNPs from the 1000 Genome project.
D. Correlation of SNP scores with densities of disease-causing variants. Genome positions were sorted by SNP score and split into 20 Mb intervals. The
plots show the average SNP score and density of disease-causing variants for each interval. The purple dotted line shows cutoff used for defining high SNP
score thereafter.
doi:10.1371/journal.pcbi.1004583.g001
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clearly stand out as more constrained than non-coding regions in general. However, a number
of non-coding elements also depart from the average genome signal, reflecting prior analysis of
the 1000 Genome project data [10]. Regions under purifying selection (ie. with high rare SNP
ratio) include evolutionarily conserved regions, transcription factor binding sites, DNase I
hypersensitive sites, early replicated and highly expressed regions. Inversely, we observed low
ratios of rare SNPs in regions of strong GC-bias, high replication rate and evolutionary con-
served RNA structures (ECS). Of note, this low ratio of rare SNP in ECS is in disagreement
with the expected deleterious effect of mutations in functional RNA structures.
We developed a Random Forest (RF) model to predict purifying selection at any genome
position based on the features present at this position. To this aim we associated every non-
coding genome position to a vector of binary values describing the presence/absence of func-
tional features at this location (see S1 Table and Methods). Following feature selection and
cross-validation, we obtained a robust model associating any combination of 16 genomic vari-
ables to a predicted rare SNP ratio. A measure of importance of each feature's contribution to
the RF model is shown in Fig 1B. Evolutionarily conserved regions, promoters and conserved
transcription factor binding sites are among the strongest contributors to rare SNP ratio, in
line with previous studies [10]. Of note, the predictive value of a high recombination rate,
which is associated to a low rare SNP ratio (Fig 1A), had not been reported before.
To evaluate how the SNP model alone can predict deleterious mutation in the non-coding
genome, we compared the average scoring of one million random SNPs to that of non-coding
variants from two distinct collections of disease-related mutations, the Clivariant [28] and
HGMD [29] databases (Fig 1C). Known clinical variants from either database have signifi-
cantly higher scores by the SNP model than random variants (Wilcoxon P<2.2e-16 in both
cases). Furthermore, scores in the SNP model are positively correlated to the density of dis-
ease-related SNPs (Fig 1D, r = 0.80 and 0.73, P = 6.09e-08 and 3.15e-06 for Clivariant and
HGMD, respectively), which confirms the capacity of the SNP model to identify non-coding
regions where mutations are more likely to be disease-related.
Scoring mutations with the somatic (SOM) model
The tumor mutational landscape results from the combined action of multiple factors includ-
ing mutagenic agents, accelerated cell division, impairment of DNA replication/repair path-
ways and resistance to treatment [13]. The tumor genome is thus subject to a set of constraints
that are quite distinct from those acting in the germline. To analyze these constraints, we col-
lected somatic mutation data from whole genome sequencing of liver cancer (N = 88 patients),
chronic lymphocytic leukemia (CLL) (N = 28), lung adenocarcinoma (N = 24) [11] and mela-
noma (N = 25) [30]. We analyzed mutation densities for the above genomic features and for
tissue-specific features such as histone marks, early/late replicated regions and transcript abun-
dance obtained from tissue-matched Encode cell lines [27](S2 Table). Results are shown in Fig
2A, S1A Fig, S2A Fig and S3A Fig. Protein-coding sequences (CDS) harbor relatively low
somatic mutation densities compared to introns (intron.P) and intergenic regions in all four
cancer types, consistent with higher functional constraints in CDS, as observed in the SNP
model. However, other features reveal a quite different pattern. Evolutionary conserved
regions, cTFBS and UTRs that were all under strong selective constraints in the germline
model present highly variable mutation densities in tumors, with densities ranging from low
(CDS level) to high (intergenic level), and no consistent pattern from tumor to tumor (Fig 2A,
S1A Fig, S2A Fig and S3A Fig). Certain features, however, present marked and consistent
mutational patterns across all four tumors. For instance, we observed an obvious trend for
accelerated mutation rates (higher density) in regions of repressed chromatin marks
Scoring Non-coding Cancer Mutations
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Fig 2. Construction of the Somatic Mutation (SOM) model for liver cancer. A. Relative density of somatic mutations from whole genome sequences of
88 liver tumors [11], associated to different genome features (see Methods for feature details). Mutation density is normalized so that the whole genome
average has a mutation density of 1. PC gene: protein coding gene; CDS: coding sequence; Exon.P, Intron.P, Exon.L,Intron.L are exon and intron of protein
coding gene and lncRNA respectively; CR: conserved region; DNase: DNase I hypersensitive site; ECS: evolutionarily conserved structure; ncExon: non-
coding exon; PC gene.HE, LncRNA.HE, PC gene.LE and LncRNA.LE are high expressed and low expressed protein coding gene and lncRNA; PC gene.
early, LncRNA.early, PC gene.late and LncRNA.late are early and late replicated protein coding gene and lncRNA; cTFBS: conserved transcription factor
binding site;RR H,RR L,GC H,GC L,DNA.met H and DNA.met L are 1-Kb windows with high recombination rate (> 4.0), low recombination rate (< 0.5), high
GC content (GC% > 50%), low GC content (GC%<30%), high DNAmethylation (average value > 0.7245) and low DNAmethylation (average
value < 0.4062) respectively; Blue and red dotted lines: base lines showing average values for CDS and intergenic regions, respectively; B: Feature
importance as measured by IncNodePurity. We only show here features that passed feature selection.C. Distribution of SOM scores for neutral SNPs and
for clinical variants from two disease-causing variants databases Clivariant and HGMD. Neutral SNPs here are SNPs from the 1000 Genome project with
allele frequency higher than 0.01, SOM scores predicted by the random forest model were divided by the number of patients.D. Correlation of SOM score
with densities of disease-causing variants. Genome positions were sorted by SOM score and split into 100Mb intervals. The plots show the average SOM
score and density of disease-causing variants for each interval. The purple dotted line shows cutoff used for defining low SOM score thereafter.
doi:10.1371/journal.pcbi.1004583.g002
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(H3K9me3), late replication (PCgene.late, lncRNA.late), low transcript expression (PCgene.LE,
lncRNA.LE) and low GC (GC L). Conversely, we observed consistently reduced mutation rates
in regions of active chromatin marks (H3K4me1-2-3, H3K79me2, H4K20me1), early replica-
tion (PCgene.early, lncRNA.early), high transcript expression (PCgene.HE, lncRNA.HE) and
high GC (GC H). The general trends in feature-wise mutation densities largely reflect prior
findings based on smaller datasets. Schuster-Bockler and Lehner [25] observed strong correla-
tions between chromatin states and mutation densities in tumors, with repressive marks linked
to higher mutation rates, possibly due to deficient DNA repair in these regions. Mutation den-
sity is also known to correlate positively with late replication [13,31,32] and negatively with
recombination rate [25] and RNA expression level [33][13].
To model the mutational constraints acting on the tumor genome, we developed a second
RF model, referred to as the SOMmodel, which predicts somatic mutation densities (the
response variable) at any genome position based on the presence of cell-specific and generic
genome features. We built one SOMmodel for each of the four above cancer types. Due to the
large number of features in the SOMmodel and limited number of somatic mutations in the
training sets, we computed feature coverage or average values (see methods) on successive 1Mb
regions and trained the RF model based on the resulting vectors. After feature selection and
robustness testing by cross-validation, the SOMmodel enabled reliable prediction of somatic
mutation density at any genome location for each cancer type (see Methods). Fig 2B, S1B Fig,
S2B Fig and S3B Fig show the importance of features in the SOMmodels.
RNA expression levels turned out to be relatively weak predictors of mutation density,
whereas replication time and histone marks in general were the predominant features deter-
mining somatic mutation density in all cancer types. However we observed significant differ-
ences between cancers. For instance the H3K36me3 mark is an important predictor of low
mutation density in melanoma and lung cancer, not in CLL or liver cancer. Also, CTCF bind-
ing sites are strong predictors of low mutation density in CLL and not in other cancer. Alto-
gether this indicates that each somatic model predicts a cancer-specific mutation profile with
distinct regions of high and low mutation densities.
Under a neutral evolutionary model, somatic mutations should freely accumulate in regions
that do not impact tumor fitness, thus regions of elevated tumor densities (high SOM score)
should be considered as generally irrelevant to fitness, while regions that are relatively pre-
served from somatic mutations (low SOM score) are potentially the most interesting as they
could reveal purifying selection occurring at the tumor level. One way to test this hypothesis is
to relate low mutation regions and the occurrence of known disease mutations. Fig 2C, S1C
Fig, S2C Fig and S3C Fig show that non-coding disease mutations from the Clivariant and
HGMD databases have significantly lower SOM scores than evolutionarily neutral SNPs (Wil-
coxon P<2.2e-16 in all cases). Furthermore, the SOM score of different genome regions is
inversely correlated to the density of disease causing variants in these regions (Fig 2D, S1D Fig,
S2D Fig and S3D Fig) (r = -0.47 to -0.94, P = 0.01 to 8.61e-14) suggesting that genome regions
spared from somatic mutations are functionally relevant to disease progression.
To further assess the value of SOM score as an indicator of selection, we mapped the
genome positions with lowest SOM scores onto the different genome features and measured
the relative enrichment for low SOM score positions within each feature (S4A Fig). Expectedly,
features that were part of the SOMmodel are significantly enriched or depleted in low SOM
scores. However, 5' and 3' splice sites, two features that were not part of the model, show a
much higher coverage by low SOM score regions than intronic regions, which indicates func-
tional non-coding elements tend to attract fewer somatic mutations, as expected under a nega-
tive selection model. This effect is also observed in lncRNA, consistent with the higher
conservation of splice junctions in this class of genes [34]. Conversely, features enriched in
Scoring Non-coding Cancer Mutations
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004583 November 20, 2015 7 / 17
high SOM scores (S4B Fig) predominantly correspond to silent regions (intergenic, centro-
meres and telomeres). In summary low SOM score positions tend to colocalize with functional
elements and correlate with disease-causing mutations, suggesting the SOMmodel could be a
significant, independent source of functional information on non-coding regions.
Towards an integrated model for germline and somatic mutations
Analysis of germline and somatic mutations suggests that each mutational regime carries valu-
able independent information about selective forces acting in a tumor. We thus questioned
whether combining SNP and SOM information at each genome position may lead to improved
mutation prioritization in cancer.
Fig 3 presents the relationship between SNP and SOM scores for one million random
genome positions and for known clinical variants. Although SNP and SOM scores are generally
uncorrelated, the roughly triangular shape of the right side of the spectrum (pointing to the
lower-right) shows that strong purifying selection (high SNP score) tends to associate with low
tumor mutation rates (low SOM score). Disease-causing variants are loosely concentrated in
Fig 3. Relationship between SNP and SOM scores in liver cancer.Grey dots: 1 million random genome positions; cyan contour: HGMD disease-causing
variant positions; red contour: Clivariant positions. The top and right curves showmarginal distributions of SNP scores (top) and SOM scores (right) for
random genome positions, HGMD and Clivariant disease-causing variant positions. Dotted lines define cutoff values for hypomutated/hypermutated regions.
SNP score cutoff = 0.63 (98.16Mb above cutoff), SOM score cutoffs = 3.10 variants/Mb, defining areas below cutoff of 55.67 Mb, in liver cancer.
Hypomutated regions defined by both cutoff correspond to ~56Mb in liver cancer type.
doi:10.1371/journal.pcbi.1004583.g003
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this lower-right corner, consistent with these positions being both under negative selection in
the germline and relatively preserved from mutational damage in the tumor. This region can
be empirically delineated by a SNP score cutoff encompassing the 100Mb highest scores (con-
stant for all cancer types) and a SOM score cutoff defined in such a way that most disease caus-
ing mutations are found below this cutoff in liver cancer (Fig 3 dashed line). These criteria
define two regions of interest in the high SNP score area of the mutational spectrum, that we
will term "hypomutated" and "hypermutated", with reference to somatic mutations (Fig 3). We
set the SOM cutoffs in the different cancer types (S5 Fig) so that the hypomutated area has the
same size (56Mb) as in liver cancer.
To assess the benefits of the joint model for scoring disease mutations, we measured disease
variant densities in different areas of each tumor spectrum using the above cutoffs (S3 Table,
S6 Fig). If we intersect high-SNP and low-SOM regions, the resulting genome area shows a
greater enrichment in disease variants than either region taken independently (χ2 P<2.2e-16
for all four cancers). Therefore we argue that integrating germline and somatic mutational
models provide a better system for prioritizing damaging mutation than any model used
independently.
Hypomutated positions are significantly over-represented within splice junctions, UTRs
and different classes of cancer genes. We mapped predicted hypomutated positions on differ-
ent genome features and gene types (Fig 4). As expected, functional features of protein-coding
genes such as intron junctions and UTRs are strongly enriched for hypomutated positions
Fig 4. Enrichment for hypomutated positions within different genome features (A) and gene classes (B). Positive values indicate enrichment,
negative values indicate depletion. Hypomutated (high SNP, low SOM) positions were mapped onto genome features (A) or genes from three different
classes (Protein-coding, lncRNA, miRNA) (B). For each feature or gene class, enrichment for hypomutated positions was computed as explained in Methods.
As hypomutated positions are cancer-specific, different results are obtained for each cancer class (colored dots). Shaded grey areas show enrichment
ranges obtained from 1000 random permutations (see Methods).
doi:10.1371/journal.pcbi.1004583.g004
Scoring Non-coding Cancer Mutations
PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004583 November 20, 2015 9 / 17
(Fig 4A). Similar trends are observed in lncRNA genes. Both lncRNA introns and exons are
generally depleted for hypomutated regions (Fig 4), in line with poor selective pressure in
lncRNA overall. However, lncRNA splice sites are slightly, albeit significantly, enriched in
hypomutated regions, consistent with previous studies showing increased purifying selection at
lncRNA splice sites [34].
We then compared hypomutated position enrichment in cancer vs. non-cancer genes.
Cancer-related protein-coding genes and cancer-related miRNAs are enriched for hypomutated
regions compared to their non-cancer counterparts (Fig 4B, S4 Table). This result suggests an ele-
vated protection from somatic and germline mutations in cancer miRNAs and in the introns and
UTRs of known cancer genes (we remind our analysis only considers the non-coding part of
genes). However, we did not observe a significant enrichment for hypomutated regions in our
short list of cancer-related lncRNAs (N = 25). Complete lists of protein-coding, lncRNA and
miRNA genes with their fraction of hypomutated positions are provided as S1 Dataset. Notable
cancer genes with high fractions of hypomutated positions include PIM1 andMED12, with
respectively 34% and 32% of their non-coding length that is hypomutated. Among cancer miR-
NAs, miR-1 and miR-574 are both covered almost completely by hypomutated positions.
Interestingly, genes with high fractions of hypermutated positions are more divergent
between cancer types than genes with high fractions of hypomutated positions (S7 Fig), sug-
gesting areas of high mutation density are largely cancer-specific, while areas of low mutation
density tend to locate in the same functional regions of the genome. GO-term biases in these
gene sets are significant only for genes enriched for hypermutated positions in liver cancer and
CLL, and involve transcription regulation functions (S5 Table).
Discussion
We introduced novel computational models to assess mutational constraints in the non-coding
genome based on the presence of functional features. We trained a model on germline SNP
data to predict rare SNP ratio at any genome site, and we trained four cancer-specific models
on tumor data to predict somatic mutation densities. These models thus provide two indepen-
dent measures of mutational constraints that are both relevant to the analysis of non-coding
regions in the cancer context. Furthermore, the feature-based model construction enabled us
to analyze the contribution of each feature to the germline and tumor mutation landscape and
to characterize the main differences between the two mutational regimens.
A major point we want to highlight in this study is that combining germline and somatic
data provide an improved definition of non-coding regions that are sensitive to mutation in
cancer cells. To illustrate this point, we extracted genome areas combining a high rare SNP
ratio and a low somatic mutation density and showed these combined criteria are a better pre-
dictor of disease causing mutation than rare SNP ratio or somatic mutation density considered
independently.
Distinctly from current models that consider somatic mutation only as a corrective mean to
avoid overpredicting deleterious mutations in highly mutated regions [10,13,22], our approach
thus considers somatic mutations on a par with evolutionary mutations, that is as a criterion to
tell apart genome positions that are neutral (highly mutated) or under purifying selection
(lowly mutated) in the tumor genome. We remind that prevalent forces shaping the tumor
mutation landscape are the combined actions of mutagens and the DNA repair machinery on
differentially accessible genome regions [25,35,36]. Therefore, if functional areas are relatively
spared from mutation, this is mostly not as a result of purifying selection, but because they are
under the closer watch of DNA repair systems. Hence the somatic model can be viewed pri-
marily as a way to discard regions sustaining accelerated mutations. However, we showed that
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hypomutated regions were enriched in functional elements such as splice junctions, which sug-
gests purifying selection may occur as well.
We are aware of the limited accuracy of somatic models when these are trained over tumors
with low mutation rates and/or few available whole genome datasets. Currently, there are far
fewer mutations to learn from in the tumor dataset than in the human polymorphism dataset
(aggregate mutation densities in the present cancer datasets ranged from 20 to 600 mutations per
Mb, vs.>12,000 SNP per Mb in the 1000 Genome data). This limits our ability to observe small-
scale variations in mutation density. We expect that the fast accumulation of whole tumor
sequences will improve model accuracy within each cancer type and provide independent valida-
tion of our approach on other tumor classes. Another potential limitation in SOMmodels is the
use of expression and epigenetic features from cell lines as a proxy for cancer tissues. This should
also improve in the future as such information is acquired from primary tumor tissues.
A key outcome of our study is a new approach to prioritize non-coding variations for cancer
driver search. Our models predict mutational constraints at a genome position based on
generic features, that is, largely independently of the actual mutations observed at this specific
location. Therefore, a locus may be predicted as hypomutated by the model and yet turn out to
sustain recurrent mutations across patients. Such a locus should then be prioritized as a candi-
date driver. Such analyses will be natural extensions of the present study.
Although cancer research now acknowledges the importance of non-coding drivers, the
search for cancer-related mutations has focused on regulatory elements such as promoters and
enhancers as the key non-coding elements [10,24]. The realization that nearly 60,000 lncRNAs
are expressed, often specifically, in tumoral genomes, many of them harboring potential disease
causing mutations [4], combined to the regulatory roles played by many lncRNAs [37] indicate
that cancer driver search should also encompass those larger transcribed regions. Even if only
10% of lncRNAs are functional by conservative estimates [5], this corresponds to a much larger
genome area than known regulatory elements. Currently, the search for cancer genes in these
non-coding RNAs is driven by expression signature analysis. We show here that the analysis of
germline and somatic mutational regimen is an important alternative that may lead to the
identification of cancer-driving elements in ncRNA genes, as well as in the non-coding fraction
of mRNA genes.
Materials and Methods
Human polymorphism, mutation and disease data
Human polymorphism data comprising 38,248,779 SNPs were downloaded from the 1000
Genome project pilot 1 [21] (http://www.1000genomes.org). The data set contains SNP data
from 2500 individuals from about 25 world populations. SNPs with allele frequency lower than
0.01 were defined as rare, other SNPs were considered neutral.
Somatic variants were collected from whole genome sequencing of paired cancer and nor-
mal tissues, obtained from two studies: 2,011,261 variants from 25 melanoma patients [30],
1,845,976 from 24 lung adenocarcinoma patients, 881,136 from 88 liver cancer patients and
59,993 from 28 chronic lymphocytic leukemia (CLL) patients [13]. Variants described as "sub-
stitution" or "indel" were both collected and are referred to collectively as mutations in the text.
Curated disease-related variants were obtained from the Clivariant (Version 2014/03/03,
55,689 variants) [28] and HGMD (Version 2014/04/14, 166,768 variants) databases [29]. After
exclusion of coding positions we used 13,108 HGMD and 6045 Clivariant mutations.
Lists of cancer genes for Fig 4 were obtained as follows: protein-coding cancer genes are
from the Cancer Gene census, available from COSMIC release V71 (http://cancer.sanger.ac.uk/
cancergenome/projects/census/) [38]; cancer-related lncRNAs are 25 mammalian long
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non-coding transcripts identified from our literature search as experimentally associated with
different cancer types (S6 Table); cancer miRNAs are from the miRCancer database [39].
Uniform genome-wide features
Uniform features used in all figures and models are summarized in S1 Table. Human genome
annotation (protein-coding and lncRNA genes, exons, introns, CDS, UTRs, non-coding Exons
(ncExon) was obtained from Gencode V7 [3]. We defined as intergenic those regions covered
by neither a protein-coding gene (including introns) nor an lncRNA. We defined as 5’ and 3'
splice sites intron regions spanning the first 10 nt on the 5' side and the last 50 nt on the 3' side.
GC contents were computed directly from the HG19 human genome assembly. We defined
1kb regions with> 50% GC as high GC and 1kb regions with< 30% GC as low GC. For the
SOMmodel, GC contents were computed over 1Mb windows.
Promoters, defined as regions of 2.5kb from transcription start site (TSS), are from the Ger-
stein lab (http://funseq.gersteinlab.org/data) [10]. Enhancers are from the Atlas of active in
vivo-transcribed enhancers, collected based on FANTOM5 CAGE data from multiple tissues
and cell lines [40]. TFBSs combine all transcription factor binding sites from more than 30
Encode cell lines [27]. Conserved TFBS (cTFBS) are from the UCSC tfbsConsSite track estab-
lished from human/mouse/rat alignment [41].
"Sensitive regions" are defined in the Khurana et al. study of genome regions under purify-
ing selection as the 0.4% genome fraction with highest enrichment in rare SNPs [10]. Evolu-
tionarily conserved regions (CR) are from the UCSC 46 mammalian genome alignment
(Phastcons score>177) [41]. Evolutionarily conserved structures (ECS) are RNA secondary
structures predicted using comparative structure prediction algorithms based on multiple
genome alignments [42]. DNase I hypersensitive sites (DNase I) from 125 combined ENCODE
cell lines were obtained directly from the UCSC web site [27].
We defined early and late replication regions using the ENCODE ‘Repli-seq' track (http://
genome.ucsc.edu/ENCODE) that provides signals for cell cycle fractions G1b, S1, S4, G2 in dif-
ferent cell types [27]. For each protein-coding or lncRNA gene, we computed the early-to-late
(E/L) ratio as (G1b+S1)/(S4+G2) averaged over the gene length. Early and late replicated genes
denote genes or lncRNAs with an E/L ratio> 1 or< 1 for all 10 cell lines respectively:
Gm12878, Hela3, Hepg2, Mcf7, Imr90, K562, Bg02es, Huvec, Bj and SK-N-SH.
Expression levels were calculated using number of reads per kilobase per million reads
(RPKM). We defined as High Expression (HE) genes those with RPKM> 20 in any of the 27
Encode cell lines [27], corresponding to the top 6% of protein coding genes for a single Encode
cell line.
Recombination rates (RR) are from the International HapMap Project (http://hapmap.ncbi.
nlm.nih.gov/) [43]. As every genome position did not have an associated RR, we averaged Hap-
Map RR values over 1kb windows. High replication rate (RRH) and low replication rate (RRL)
regions were defined by an average replication rate above 4.0 or below 0.5, respectively.
Tissue-specific features
RNA expression levels, transcription factor binding sites (TFBS) and maps of histone modifica-
tion marks were acquired from UCSC ENCODE tracks [27] for each cell type: Hepg2, A549,
K562, Nhdfad (S2 Table). Replication timings were acquired from UCSC ENCODE tracks for
cell lines Hepg2, lmr90, K562, Bg02 (S2 Table).
To define high expression and low expression genes, expression levels were measured for a
single randomly selected cell line from the same tissue for each independent protein coding
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gene and lncRNA. RPKM values above 20 and below 0.25 defined high (PCgene.HE, lncRNA.
HE) and low expression genes (PCgene.LE, lncRNA.LE), respectively.
Replication timings were defined for each protein-coding gene and lncRNA using the same
E/L calculation as above. Genes with an E/L ratio> 1 were considered early replicated
(lncRNA.early, PCgene.early), genes with an E/L ratio< 1 were considered late replicated
(lncRNA.late, PCgene.late).
DNA methylation data were obtained from TCGA database for cancer types liver hepatocel-
luar carcinoma, lung adenocarcinoma, acute myeloid leukemia and skin cutaneous melanoma.
Average DNAmethylation value was computed for each methylation site across multiple
patients using available values. Undefined values were then replaced with mean and we aver-
aged DNA methylation over non-overlapping 1Kb and 1Mb windows. 1Kb windows with
mean DNA methylation values greater than 0.7245 and less than 0.4062 were defined as high
(DNA.met H) and low (DNA.met L) DNAmethylation windows respectively.
Rare SNP model
A random forest (RF) is an ensemble of multiple decision trees computed from separate boot-
strap samples of the training data and feature set [44]. We developed the germline RF model
(SNP model) to predict the density of rare SNP at any genome location based on 14 distinct
features (S1 Table). The response variable was the local ratio of rare SNP (number of rare
SNPs /total number of SNPs) obtained from the 1000 Genome Project.
A matrix of 44130 rows was formed after removal of those combinations in coding regions,
each row representing one type of combination of features that can be observed throughout the
non-coding genome. Feature selection was performed with the R VSURF package [45], result-
ing in elimination of features GC (S1 Table) and late replicated regions, leaving18656 combina-
tions of the remaining 16 features. 2502 combinations of 16 features containing 99.49% of
SNPs and 99.50% of the human genome were used to train the model after removal of the com-
binations of size smaller than 10Kb. The RF model was produced using the R randomForest
package. The SNP score was predicted with the 16 selected features for each combination of
feature in the non-coding genome. Model calibration and cross validation are presented in S1
Text. Variable importance (Fig 1B) was estimated using node purity, which measures the
decrease in tree node purity that results from splits of a given variable.
Somatic mutation model
The somatic (SOM) RF model was built using as predictors the 16 uniform and 17 tissue-spe-
cific features described in S1 Table and S2 Table, and as response variable the local density of
somatic mutation across all tumors in the cancer type under study. Due to the relatively sparse
somatic mutation data, model fitting was performed using continuous variables measured for
genome windows as explained below.
Features ncExon, introns of lncRNAs and PC genes, CR, cTFBS, UTR, Promoter, GC con-
tents and the various histone marks were expressed as the number of nucleotides covered by
the feature within each successive 1Mb window. Features recombination rate, DNAmethyla-
tion, replication time and expression level were computed for each successive 1Mb window as
follows. To obtain expression levels for 1Mb windows, RNA-seq reads from each cell lines (3
samples/cell line) were counted, and the length of exons from Gencode annotation was calcu-
lated, then, average expression level was calculated as RPKM. Replication time in the SOM
model was the average E/L ratio computed as above for each 1Mb window. Recombination rate
and DNA methylation were averaged over non-overlapping 1-Mb windows across the genome.
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The SOMmodel used cancer mutation density as the response variable and the 33 genomic
features (32 for lung cancer) as predictor variables. A matrix of 2846 rows was formed, of
which each row represents a 1-Mb window and columns contain values of genomic features
and response variable. For model fitting, we discarded genome regions with poor annotation
or biased mutation information. This included any 1Mb window overlapping a telomere, cen-
tromere, stalk, pericentromere, or with 100% undefined bases, and the entire Y chromosome
due to ploidy bias (total: 224.3Mb). All predictor values were plus one and log scaled.
The RF regression model was constructed with the R randomForest package as above. Fea-
ture selection was performed with the R VSURF package [45]. Model calibration, robustness
testing/cross validation of the SOMmodels are presented in S1 Text.
For SOM score prediction, we used the same 1-Mb window strategy as in model building,
however, the 1Mb-windows were slided across the human genome with a step size of 1Kb, in
order to extrapolate to regions not used in model building. 1Mb windows unfit for model train-
ing were excluded as above, resulting in 2,832,687 overlapping 1Mb window annotations. The
SOM score was predicted using selected features for each 1Mb window and averaged on a 1 Kb
window scale.
Enrichment analysis









Where Hf = #hypomutated positions within feature, Sf = total size of feature, Hg = #hypomu-
tated positions in whole genome, Sg = total size of genome. The signiﬁcance of enrichment or
depletion was evaluated using a permutation test as follows: a set of positions of same size as
the hypomutated region (ie. 56Mb) was randomly sampled from the whole genome 1000
times, and in each random sample, enrichments were calculated for each feature class. The dis-
tribution of enrichment values from the 1000 random samples is shown as shaded areas in Fig-
ures. Only observed enrichments outside these areas are considered signiﬁcant. Enrichment for
other types of positions (hypermutated, low SOM score etc.) was evaluated similarly.
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